A Phase 4 interventional study of Orlistat in Obesity, sponsored by Albany College of Pharmacy and Health Sciences. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-04.
Sponsored by Albany College of Pharmacy and Health Sciences · Phase 4, Interventional, and Treatment
The primary goal of the study is to determine if orlistat 60mg (Alli) is effective in helping patients achieve a required 10% weight loss goal prior to bariatric surgery. The medication will be added to the usual standard of care which includes education regarding diet and exercise and monthly meetings with a registered dietician.
6,570 studies on the registry are indexed under Obesity; 1,718 are open to participants now.
This study's enrollment of 19 is below the median of 77 across 5,084 interventional studies indexed under Obesity.
Browse Obesity studies →Albany College of Pharmacy and Health Sciences is the lead sponsor of 5 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients assigned to treatment group for up to 6 months of therapy.
Drug: Orlistat
60mg capsule three times a day for up to 6 months
Also known as: Alli
Weight Loss
Weight loss acheived during time on study up to 6 months.
Time frame: 6 months
Patient Satisfaction
Time frame: 6 months
Dates of recruitment 10.14.09 to 12.15.10 Outpatient clinic, Bariatric treatment Center
| Milestone | Orlistat 60mg |
|---|---|
| Started | 19 |
| Completed | 9 |
| Not completed | 10 |
Weight loss acheived during time on study up to 6 months.
| percentage of weight | Orlistat 60mg |
|---|---|
| Weight Loss | 2.0 ± 3.4 |
| participants | Orlistat 60mg |
|---|---|
| Patient Satisfaction | 9 |
Collected over 6 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Orlistat 60mg | — | 0/19 (0%) | 0/19 (0%) |
| Age, Categorical(Participants) | Orlistat 60mg |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 19 |
| >=65 years | 0 |
| Age, Continuous(years) | Orlistat 60mg |
|---|---|
| Mean | 40.9 ± 11.4 |
| Sex: Female, Male(Participants) | Orlistat 60mg |
|---|---|
| Female | 14 |
| Male | 5 |
| Region of Enrollment(participants) | Orlistat 60mg |
|---|---|
| United States | 19 |
The record gives a start of Nov 2009, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orlistat
Albany College of Pharmacy and Health Sciences